株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

コレステロール降下薬市場の予測 2015〜2025年:PCSK9阻害剤、CETP阻害剤、MTTP阻害剤、ApoB阻害剤、およびPPAR作用薬における機会

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

発行 Visiongain Ltd 商品コード 344395
出版日 ページ情報 英文 199 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=146.92円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
コレステロール降下薬市場の予測 2015〜2025年:PCSK9阻害剤、CETP阻害剤、MTTP阻害剤、ApoB阻害剤、およびPPAR作用薬における機会 Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists
出版日: 2015年11月02日 ページ情報: 英文 199 Pages
概要

コレステロール降下薬市場の全体的な収益は、2019年に246億3,000万米ドルに達すると予測されています。同市場においては、2025年まで安定した収益成長が続く見込みです。

当レポートでは、世界のコレステロール降下薬市場について取り上げ、同市場に影響を及ぼす問題、市場予測、収益予測、各2次市場における収益予測、主要地域市場における収益予測、主要企業の評価、および市場成長の促進因子・阻害因子の分析など、体系的な情報を提供しています。

第1章 調査概要

第2章 コレステロール降下薬のイントロダクション

  • 医薬品産業:概要
  • コレステロール:必要不可欠な脂質
  • コレステロールの機能
  • コレステロールの代謝および循環
  • 心臓病におけるコレステロールの役割
  • 心臓病におけるコレステロールの役割:通説
  • 心臓病におけるコレステロールの役割:議論
  • HDLコレステロールの増加:価値のある目的?
  • 高コレステロール血症の原因
  • 高コレステロール血症の治療
  • コレステロール降下薬の分類
  • 治験の段階
  • 調査範囲
  • 本調査における為替通貨レート

第3章 コレステロール降下薬:世界市場

  • 世界のコレステロール降下薬市場
  • 世界のコレステロール降下薬市場:売上予測
  • コレステロール降下薬市場区分:売上予測
  • 市場シェアの変化:区分別

第4章 主要国市場

  • 世界におけるコレステロール降下薬市場の地域分析
  • 世界におけるコレステロール降下薬市場の国別分析
  • 米国におけるコレステロール降下薬市場
  • 欧州の主要5か国におけるコレステロール降下薬市場
  • BRIC諸国におけるコレステロール降下薬市場
  • 日本におけるコレステロール降下薬市場

第5章 スタチンおよび多剤混合薬 (FDC) :市場・パイプライン

  • スタチン:HMG-CoA レダクターゼの阻害
  • スタチンおよび多剤混合薬 (FDC) 市場
  • スタチンおよび多剤混合薬 (FDC) :市場予測
  • 製品の市場シェア変動予測
  • Crestor (Rosuvastatin, AstraZeneca)
  • Lipitor (Atorvastatin, Pfizer)
  • Livalo (Pitavastatin, 興和)
  • Lescol ・ Lescol XL (Fluvastatin, Novartis)
  • Zocor: 売上予測
  • 多剤混合薬 (FDC)
  • Vytorin (Simvastatin/Ezetimibe, Merck)
  • Caduet (Atorvastatin/Amlodipine, Pfizer)

第6章 吸収阻害剤、イオン交換樹脂、フィブラート系薬およびその他の医薬品:市場・パイプライン

  • 吸収阻害剤、イオン交換樹脂、フィブラート系薬およびその他の医薬品:概要
  • イオン交換樹脂、フィブラート系薬およびその他の医薬品市場
  • イオン交換樹脂、フィブラート系薬およびその他の医薬品:市場予測
  • 製品の市場シェア変動予測
  • Zetia (Ezetimibe, Merck)
  • Welchol (Colesevelam, 第一三共)
  • Tricor (Fenofibrate, AbbVie)

第7章 PCSK9阻害剤:市場・パイプライン

  • PCSK9阻害剤:次のベストセラー薬剤クラスか?
  • 治験中のPCSK9阻害剤
  • PCSK9阻害剤およびスタチン
  • PCSK9阻害剤:市場予測
  • 製品の市場シェア変動予測
  • PCSK9阻害剤:パイプライン分析
  • Praluent (Alirocumab, Sanofi/Regeneron)
  • Repatha (Evolocumab, Amgen)
  • RN316 (Bococizumab, Pfizer)
  • PCSK9 経口阻害剤 (Pfizer)
  • PF-06427878 (Pfizer)
  • PCSK9 ワクチン (Pfizer)
  • SX-PCK9 (Serometrix)
  • 開発が中止されたパイプライン製品

第8章 新規コレステロール降下薬:市場・パイプライン

  • 新規コレステロール降下薬:概要
  • 新規コレステロール降下薬市場
  • 新規コレステロール降下薬:市場予測
  • 製品の市場シェア変動予測
  • CETP阻害剤:概要
  • MTTP阻害剤:市場およびパイプライン分析
  • ApoB素材材:市場およびパイプライン分析
  • その他の薬剤クラス:市場およびパイプライン分析
  • 開発が中止されたパイプライン製品

第9章 コレステロール降下薬市場における主要企業

  • コレステロール降下薬の主要メーカー
  • AstraZeneca
  • Merck
  • Pfizer
  • 興和
  • 第一三共
  • AbbVie
  • Novartis
  • Sanofi
  • Amgen

第10章 コレステロール降下薬市場の定性分析

  • コレステロール降下薬市場のSWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ポーターのファイブフォース分析

第11章 結論

第12章 用語集

図表一覧

目次
Product Code: PHA0076

What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 199-page report provides 153 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

image1

image2

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2025? Our study forecasts revenues in the following cholesterol-lowering drugs submarkets and products:

  • Statins and Fixed-Dose Combinations
    • Crestor
    • Lipitor
    • Livalo
    • Lescol/Lescol XL
    • Zocor
    • Vytorin
    • Caduet
    • Other Statins and Fixed-Dose Combinations (grouped forecast)
  • Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs
    • Zetia
    • Welchol
    • Tricor
    • Other cholesterol-lowering drugs (grouped forecast)
  • PCSK9 Inhibitors
    • Praluent
    • Repatha
    • RN316
    • Other PCSK9 Inhibitors (grouped forecast)
  • Novel Cholesterol-Lowering Drugs
    • Juxtapid
    • Kynamro
    • MK-0859
    • Other novel cholesterol-lowering drugs (grouped forecast)

image3

See revenue forecasts for the leading international markets

How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:

  • US
  • Japan
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • China
  • Brazil
  • Russia
  • India

Leading companies and potential for market growth

Overall revenue for the cholesterol-lowering drugs market will reach $24.63bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. Shifts in diets and lifestyles will contribute to rising levels of high cholesterol, while highly disruptive new treatments will revitalise the market

Our work analyses the key companies in the market. See visiongain's analysis of 9 leading companies, including these:

  • AstraZeneca
  • Merck
  • Pfizer
  • Kowa
  • Daiichi Sankyo
  • Abbvie
  • Novartis
  • Sanofi
  • Amgen

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Analysis of products currently on the market as well as pipeline products
  • Company news relevant to the market

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Cholesterol-Lowering Drugs industry?

Our new report discusses issues and events affecting the cholesterol-lowering drugs market. You will find discussions, including qualitative analyses:

  • Highly disruptive treatments entering the market
  • Increasing potential in both established and emerging markets

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Cholesterol-Lowering Drugs Market Forecast 2015-2025 report helps you

In summary, our 199-page report gives you the following knowledge:

  • Revenue forecasts to 2025 for the Cholesterol-Lowering Drugs market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2025 for submarkets in each - statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs
  • Revenue forecasts to 2025 for the leading regional markets - US, Japan, EU5 and BRIC
  • Assessment of 9 leading companies - analysis of cholesterol-lowering products, revenue, news and upcoming product releases
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the cholesterol-lowering drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

Table of Contents

1. Report Overview

  • 1.1 Global Cholesterol-Lowering Drugs Market Overview
  • 1.2 Global Cholesterol-Lowering Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Introduction to Cholesterol-Lowering Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Overview
  • 2.2 Cholesterol: An Essential Lipid
  • 2.3 The Functions of Cholesterol
  • 2.4 Metabolism and Circulation of Cholesterol
  • 2.5 The Role of Cholesterol in Heart Disease
  • 2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy
    • 2.6.1 The IMPROVE-IT Study
  • 2.7 The Role of Cholesterol in Heart Disease: The Controversy
  • 2.8 Raising HDL Cholesterol: A Worthwhile Aim?
  • 2.9 Causes of Hypercholesterolaemia
  • 2.9.1 Atherosclerosis
  • 2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia
  • 2.9.3 Familial Hypercholesterolaemia
  • 2.10 Treatment of Hypercholesterolaemia
    • 2.10.1 UK Treatment Guidelines for Hypercholesterolaemia
    • 2.10.2 US Treatment Guidelines for Hypercholesterolaemia
    • 2.10.3 Lifestyle Changes
    • 2.10.4 Drugs to Lower Cholesterol
    • 2.10.5 Other Therapeutic Approaches
    • 2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment
    • 2.10.5.2 LDL Apheresis: Directly Removing Cholesterol
    • 2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia
  • 2.11 Classification of Cholesterol-Lowering Drugs
    • 2.11.1 Statins
    • 2.11.2 Selective Cholesterol Absorption Inhibitors
    • 2.11.3 Ion Exchange Resins
    • 2.11.4 Fibrates
    • 2.11.5 Other Cholesterol-Lowering Drugs
    • 2.11.6 Novel Cholesterol-Lowering Drugs
    • 2.11.7 PCSK9 Inhibitors
  • 2.12 Phases of Clinical Trials
  • 2.13 Scope of This Report
    • 2.13.1 Products Excluded from This Report
  • 2.14 Currency Exchange Rates in This Report

3. Cholesterol-Lowering Drugs: World Market 2015-2025

  • 3.1 The World Cholesterol-Lowering Drugs Market in 2014
    • 3.1.1 Leading Cholesterol-Lowering Drugs Products
    • 3.1.2 Leading Companies in the Cholesterol-Lowering Drugs Market
  • 3.2 World Cholesterol-Lowering Drugs Market: Sales Forecast 2015-2025
  • 3.3 Cholesterol-Lowering Drugs Market Segments: Sales Forecasts 2015-2025
    • 3.3.1 Cholesterol-Lowering Drugs Market Segmentation
  • 3.4 Changing Market Shares by Segment 2015-2025
    • 3.4.1 World Cholesterol-Lowering Drugs Market: Drivers and Restraints 2015-2025

4. Leading National Markets, 2015-2025

  • 4.1 Regional Breakdown of the World Cholesterol-Lowering Drugs Market
    • 4.1.1 World Cholesterol-Lowering Drugs Market: Regional Forecast 2015-2025
    • 4.1.2 How Will Regional Market Shares Change to 2025?
  • 4.2 National Breakdown of the World Cholesterol-Lowering Drugs Market
    • 4.2.1 World Cholesterol-Lowering Drugs Market: National Markets Forecast 2015-2025
    • 4.2.2 How Will National Market Shares Change to 2025?
  • 4.3 The US Cholesterol-Lowering Drugs Market 2015-2025
    • 4.3.1 US Cholesterol-Lowering Drug Market Forecast 2015-2025
    • 4.3.2 US Cholesterol-Lowering Drugs Market: Drivers and Restraints
      • 4.3.2.1 High Prevalence of High Cholesterol in US
  • 4.4 The Cholesterol-Lowering Drugs Market in the Five Leading European National Markets to 2025
    • 4.4.1 EU5 Cholesterol-Lowering Drugs Market: Drivers and Restraints
    • 4.4.2 The Cholesterol-Lowering Drugs Market in Germany to 2025
      • 4.4.2.1 German Cholesterol-Lowering Drugs Market: Trends and Developments
    • 4.4.3 The Cholesterol-Lowering Drugs Market in France to 2025
      • 4.4.3.1 French Cholesterol-Lowering Drugs Market: Trends and Developments
    • 4.4.4 The Cholesterol-Lowering Drugs Market in the UK to 2025
      • 4.4.4.1 UK Cholesterol-Lowering Drugs Market: Trends and Developments
    • 4.4.5 The Cholesterol-Lowering Drugs Market in Italy to 2025
      • 4.4.5.1 Italian Cholesterol-Lowering Drugs Market: Trends and Developments
    • 4.4.6 The Cholesterol-Lowering Drugs Market in Spain to 2025
      • 4.4.6.1 Spanish Cholesterol-Lowering Drugs Market: Trends and Developments
  • 4.5 The Cholesterol-Lowering Drugs Market in the BRIC National Markets to 2025
    • 4.5.1 BRIC Cholesterol-Lowering Drugs Market: Drivers and Restraints
    • 4.5.2 The Cholesterol-Lowering Drugs Market in China to 2025
      • 4.5.2.1 Chinese Cholesterol-Lowering Drugs Market: Trends and Developments
        • 4.5.2.1.1 Economic Challenges
        • 4.5.2.1.2 Expansion of Healthcare Coverage and Reimbursement
    • 4.5.3 The Cholesterol-Lowering Drugs Market in Brazil to 2025
      • 4.5.3.1 Brazilian Cholesterol-Lowering Drugs Market: Trends and Developments
    • 4.5.4 The Cholesterol-Lowering Drugs Market in Russia to 2025
      • 4.5.4.1 Russian Cholesterol-Lowering Drugs Market: Trends and Developments
        • 4.5.4.1.1 Lower Oil Prices
        • 4.5.4.1.2 No Embargo on Foreign Drugs
    • 4.5.5 The Cholesterol-Lowering Drugs Market in India to 2025
      • 4.5.5.1 Indian Cholesterol-Lowering Drugs Market: Trends and Developments
        • 4.5.5.1.1 Drug Price Control Order 2014
        • 4.5.5.1.2 Expansion of Healthcare Provision
  • 4.6 The Cholesterol-Lowering Drugs Market in Japan to 2025
    • 4.6.1 Japanese Cholesterol-Lowering Drugs Market: Trends and Developments
      • 4.6.1.1 Generic Penetration to Reach 60% by 2018?
      • 4.6.1.2 Japanese Pharmaceutical Industry Regulatory Reform

5. Statins and Fixed-Dose Combinations: Market and Pipeline 2015-2025

  • 5.1 Statins: Inhibiting HMG-CoA Reductase
  • 5.2 The Statins and Fixed-Dose Combinations Market in 2014
  • 5.3 Statins and Fixed-Dose Combinations: Market Forecast 2015-2025
  • 5.4 How Will Market Shares of Products Change to 2025?
  • 5.5 Crestor (Rosuvastatin, AstraZeneca)
    • 5.5.1 Crestor: Historical Sales Estimate 2009-2014
    • 5.5.2 Crestor: Sales Forecast 2015-2025
    • 5.5.3 Generic Competition for Crestor
  • 5.6 Lipitor (Atorvastatin, Pfizer)
    • 5.6.1 Lipitor: Historical Sales Estimate 2009-2014
    • 5.6.2 Lipitor: Sales Forecast 2015-2025
  • 5.7 Livalo (Pitavastatin, Kowa)
    • 5.7.1 Livalo: Sales Forecast 2015-2025
  • 5.8 Lescol and Lescol XL (Fluvastatin, Novartis)
    • 5.8.1 Lescol/Lescol XL: Sales Forecast 2015-2025
  • 5.9 Zocor (Simvastatin, Merck)
    • 5.9.1 Zocor: Sales Forecast 2015-2025
  • 5.10 Fixed-Dose Combinations
  • 5.11 Vytorin (Simvastatin/Ezetimibe, Merck)
    • 5.11.1 Vytorin: Sales Forecast 2015-2025
  • 5.12 Caduet (Atorvastatin/Amlodipine, Pfizer)
    • 5.12.1 Caduet: Sales Forecast 2015-2025

6. Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market and Pipeline 2015-2025

  • 6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Overview
  • 6.2 The Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market in 2014
  • 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Forecast 2015-2025
  • 6.4 How Will Market Shares of Products Change to 2025?
  • 6.5 Zetia (Ezetimibe, Merck)
    • 6.5.1 The ENHANCE Study: No Additional Benefit
    • 6.5.2 The IMPROVE-IT Study: Reduction in Cardiovascular Risk
    • 6.5.3 Zetia: Sales Forecast 2015-2025
  • 6.6 Welchol (Colesevelam, Daiichi Sankyo)
    • 6.6.1 Threat of Imminent Generic Competition for Welchol
    • 6.6.2 Welchol: Sales Forecast 2015-2025
  • 6.7 Tricor (Fenofibrate, AbbVie)
    • 6.7.1 Generic Erosion of Tricor Sales
    • 6.7.2 Tricor: Sales Forecast 2015-2025

7. PCSK9 Inhibitors: Market and Pipeline 2015-2025

  • 7.1 PCSK9 Inhibitors: The Next Blockbuster Drug Class?
  • 7.2 PCSK9 in Clinical Trials
  • 7.3 PCSK9 Inhibitors and Statins
  • 7.4 PCSK9 Inhibitors: Market Forecast 2015-2025
  • 7.5 How Will Market Shares of Products Change to 2025?
  • 7.6 PCSK9 Inhibitors: Pipeline Analysis 2015-2025
  • 7.7 Praluent (Alirocumab, Sanofi/Regeneron)
    • 7.7.1 Praluent: Sales Forecast 2015-2025
  • 7.8 Repatha (Evolocumab, Amgen)
    • 7.8.1 GAUSS-2
    • 7.8.2 RUTHERFORD-2
    • 7.8.3 LAPLACE-2
    • 7.8.4 Repatha: Sales Forecast 2015-2025
  • 7.9 RN316 (Bococizumab, Pfizer)
    • 7.9.1 RN316: Sales Forecast 2015-2025
  • 7.10 Oral PCSK9 Inhibitor (Pfizer)
  • 7.11 PF-06427878 (Pfizer)
  • 7.12 PCSK9 Vaccine (Pfizer)
  • 7.13 SX-PCK9 (Serometrix)
  • 7.14 Discontinued Pipeline Products
    • 7.14.1 BMS-962476 (Adnectin, Bristol-Myers Squibb)
    • 7.14.2 LY3015014 (Eli Lilly)

8. Novel Cholesterol-Lowering Drugs: Market and Pipeline 2015-2025

  • 8.1 Novel Cholesterol-Lowering Drugs: Overview
  • 8.2 Novel Cholesterol-Lowering Drugs Market in 2014
  • 8.3 Novel Cholesterol-Lowering Drugs: Market Forecast 2015-2025
  • 8.4 How Will Market Shares of Products Change to 2025?
  • 8.5 CETP Inhibitors: Overview
    • 8.5.1 CETP Inhibitors: Pipeline Analysis 2015-2025
    • 8.5.2 MK-0859 (Anacetrapib, Merck)
    • 8.5.2.1 MK-0859 (Anacetrapib): Sales Forecast 2015-2025
    • 8.5.3 Dalcetrapib (DalCor)
    • 8.5.4 DEZ-001/TA-8995 (CETP Inhibitor, Dezima/Amgen)
    • 8.5.5 DRL-17822 (CETP Inhibitor, Dr. Reddy's Laboratories)
    • 8.5.6 PRC-4016 (Icosabutate, ProNova BioPharma)
    • 8.5.7 K-312 (CETP Inhibitor, Kowa)
  • 8.6 MTTP Inhibitors: Market and Pipeline Analysis 2015-2025
    • 8.6.1 Juxtapid (Lomitapide, Aegerion Pharmaceuticals)
    • 8.6.1.1 Juxtapid (Lomitapide): Sales Forecast 2015-2025
  • 8.7 ApoB Inhibitors: Market and Pipeline Analysis 2015-2025
    • 8.7.1 Kynamro (Mipomersen, Isis Pharmaceuticals/Sanofi)
    • 8.7.1.1 Kynamro (Mipomersen): Drug Launch and Pricing Strategy
    • 8.7.1.2 Kynamro (Mipomersen): Sales Forecast 2015-2025
  • 8.8 Other Drug Classes: Market and Pipeline Analysis 2015-2025
    • 8.8.1 K-877 (PPAR-Α Agonist, Kowa)
    • 8.8.2 REGN1500 (ANGPTL3 Inhibitor, Regeneron)
    • 8.8.3 ETC-1002 (ACL Inhibitor, Esperion Therapeutics)
    • 8.8.4 ALN-PCS02 and ALN-PCSsc (Alnylam)
  • 8.9 Discontinued Pipeline Products
    • 8.9.1 Torcetrapib
    • 8.9.2 LY2484595 (Evacetrapib)

9. Leading Companies in the Cholesterol-Lowering Drugs Market

  • 9.1 Leading Cholesterol-Lowering Drugs Manufacturers in 2014
    • 9.1.1 Leading Companies: Market Forecast 2015-2025
    • 9.1.2 How Will Leading Companies' Market Shares Change to 2025?
  • 9.2 AstraZeneca
    • 9.2.1 AstraZeneca: Cholesterol-Lowering Drugs
    • 9.2.2 AstraZeneca: Sales Forecast 2015-2025
    • 9.2.3 AstraZeneca: Recent Developments
    • 9.2.3.1 Cholesterol Awareness Initiative in America
    • 9.2.3.2 AstraZeneca Rejects Pfizer Takeover Bid
  • 9.3 Merck
    • 9.3.1 Merck: Cholesterol-Lowering Drugs
    • 9.3.2 Merck: Sales Forecast 2015-2025
    • 9.3.3 Merck: Recent Developments
    • 9.3.3.1 Bayer Acquires Merck's Consumer Health Business
    • 9.3.3.2 Study Shows Lower LDL Levels Are More Beneficial
  • 9.4 Pfizer
    • 9.4.1 Pfizer: Cholesterol-Lowering Drugs
    • 9.4.2 Pfizer: Sales Forecast 2015-2025
    • 9.4.3 Pfizer: Recent Developments
    • 9.4.3.1 Pfizer Ends Over-The-Counter Lipitor Program
    • 9.4.3.2 Development of Oral PCSK9 Inhibitor
  • 9.5 Kowa
    • 9.5.1 Kowa: Cholesterol-Lowering Drugs
    • 9.5.2 Kowa: Sales Forecast 2015-2025
    • 9.5.3 Kowa: Recent Developments
    • 9.5.3.1 Development of K-312
    • 9.5.3.2 Development of K-887
  • 9.6 Daiichi Sankyo
    • 9.6.1 Daiichi Sankyo: Cholesterol-Lowering Drugs
    • 9.6.2 Daiichi Sankyo: Sales Forecast 2015-2025
    • 9.6.3 Daiichi Sankyo: Recent Developments
    • 9.6.3.1 Staff Reduction at US Operation
  • 9.7 AbbVie
    • 9.7.1 AbbVie: Cholesterol-Lowering Drugs
    • 9.7.2 AbbVie: Sales Forecast 2015-2025
    • 9.7.3 AbbVie: Recent Developments
    • 9.7.3.1 Possible Marketing Cost Reductions
  • 9.8 Novartis
    • 9.8.1 Novartis: Cholesterol-Lowering Drugs
    • 9.8.2 Novartis: Sales Forecast 2015-2025
  • 9.9 Sanofi
    • 9.9.1 Sanofi: Cholesterol-Lowering Drugs
    • 9.9.2 Sanofi: Sales Forecast 2015-2025
    • 9.9.3 Sanofi: Recent Developments
    • 9.9.3.1 Purchase of Priority Review Voucher from BioMarin Pharmaceuticals
  • 9.10 Amgen
    • 9.10.1 Amgen: Cholesterol-Lowering Drugs
    • 9.10.2 Amgen: Sales Forecast 2015-2025
    • 9.10.3 Amgen: Recent Developments
    • 9.10.3.1 Amgen Sues Sanofi and Regeneron To Block Praluent

10. Qualitative Analysis of the Cholesterol-Lowering Drugs Market 2015-2025

  • 10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market
  • 10.2 Strengths
    • 10.2.1 Strong Pipeline
    • 10.2.2 High Profile Encouraging Healthcare Provision
  • 10.3 Weaknesses
    • 10.3.1 Increasing Generic Penetration
    • 10.3.2 Approved Indications Limited for New Products
  • 10.4 Opportunities
    • 10.4.1 Increasing Prevalence in Emerging Markets
    • 10.4.2 Possible Additional Indications
  • 10.5 Threats
    • 10.5.1 Patent Expiry
    • 10.5.2 Cost-Containment
  • 10.6 Porter's Five Forces Analysis of the Cholesterol-Lowering Drugs Market
    • 10.6.1 Rivalry among Competitors [High]
    • 10.6.2 Threat of New Entrants [Medium]
    • 10.6.3 Power of Suppliers [Low]
    • 10.6.4 Power of Buyers [Medium]
    • 10.6.5 Threat of Substitutes [High]

11. Conclusions

  • 11.1 The World Cholesterol-Lowering Drugs Market: 2014-2015
  • 11.2 The World Cholesterol-Lowering Drugs Market Forecast: 2014-2025

12. Glossary

List of Tables

  • Table 1.1 Leading National Cholesterol-Lowering Drugs Market Forecast 2015 ($m, AGR%)
  • Table 2.1 Clinical Trial Phases
  • Table 2.2 Currency Exchange Rates, 2014
  • Table 3.1 Top 10 Cholesterol-Lowering Drugs: Revenue ($m) and Market Share (%), 2014
  • Table 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Drug Class, 2014-2025
  • Table 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2014, 2019 and 2025
  • Table 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) and Market Shares (%) by Region, 2014
  • Table 4.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Region, 2014-2025
  • Table 4.3 Market Shares (%) of Leading Cholesterol-Lowering Drugs Market, 2014, 2019 and 2025
  • Table 4.4 World Cholesterol-Lowering Drugs Market: Revenues ($m), and Market Shares (%) by National Market, 2014
  • Table 4.5 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
  • Table 4.6 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014
  • Table 4.7 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.8 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.9 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.10 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.11 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.12 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.13 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.14 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.15 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.16 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.17 Russian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.18 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 4.19 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%) 2014-2025
  • Table 5.1 Leading Statins and Fixed-Dose Combinations: Revenue ($m) and Market Shares (%), 2014
  • Table 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%) by Drug, 2014, 2019 and 2025
  • Table 5.4 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2009-2014
  • Table 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.6 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2009-2014
  • Table 5.7 Pfizer: Lipitor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.8 Kowa: Livalo Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.9 Novartis: Lescol/Lescol XL Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.10 Merck: Zocor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.11 Merck: Vytorin Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 5.12 Pfizer: Caduet Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.1 Leading Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Revenue ($m) and Market Shares (%), 2014
  • Table 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%) by Drug, 2014, 2019 and 2025
  • Table 6.4 Merck: Zetia Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.5 Daiichi Sankyo: Welchol Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 6.6 AbbVie: Tricor Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.1 PCSK9 Inhibitors Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.2 PCSK9 Inhibitors Market: Market Shares (%) by Drug, 2015, 2019 and 2025
  • Table 7.3 Sanofi/Regeneron: Praluent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.4 Amgen: Repatha Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 7.5 Pfizer: RN316 (Bococizumab) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 8.1 Novel Cholesterol-Lowering Drugs: Revenue ($m) and Market Shares (%), 2014
  • Table 8.2 Novel Cholesterol-Lowering Drugs Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 8.3 Novel Cholesterol-Lowering Drugs Market: Market Shares (%) by Drug, 2014, 2019 and 2025
  • Table 8.4 Merck: MK-0859 (Anacetrapib) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 8.5 Aegerion Pharmaceuticals: Juxtapid (Lomitapide) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 8.6 Isis Pharmaceuticals/Sanofi: Kynamro (Mipomersen) Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 9.1 Leading Cholesterol-Lowering Drugs Manufacturers: Cholesterol-Lowering Drugs Revenue ($m), Market Share (%), 2014
  • Table 9.2 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
  • Table 9.3 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m) and Market Shares (%), 2019 and 2025
  • Table 9.4 AstraZeneca: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.5 Merck: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.6 Pfizer: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.7 Kowa: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.8 Daiichi Sankyo: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.9 AbbVie: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.10 Novartis: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.11 Sanofi: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 9.12 Amgen: Cholesterol-Lowering Drugs: Revenue ($m), AGR (%) and CAGR (%) by Drug, 2014-2025
  • Table 10.1 SWOT Analysis of the Cholesterol-Lowering Drugs Market, 2015-2025
  • Table 11.1 World Cholesterol-Lowering Drug Market Regions: Revenues ($m), 2014 and 2015
  • Table 11.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025

List of Figures

  • Figure 1.1 Global Cholesterol-Lowering Drugs Market Segmentation Overview, 2015
  • Figure 2.1 Chemical Structure of Cholesterol, 2015
  • Figure 3.1 Top 10 Cholesterol-Lowering Drugs: Market Share (%), 2014
  • Figure 3.2 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 3.3 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m) by Drug Class, 2014-2025
  • Figure 3.4 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2019
  • Figure 3.5 Market Shares (%) of Cholesterol-Lowering Drug Market Segments, 2025
  • Figure 3.6 Global Cholesterol-Lowering Drugs Market: Drivers and Restraints, 2015-2025
  • Figure 4.1 World Cholesterol-Lowering Drugs Market: Revenues ($m) by Region, 2014
  • Figure 4.2 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2014
  • Figure 4.3 World Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) by Region, 2014-2025
  • Figure 4.4 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2019
  • Figure 4.5 World Cholesterol-Lowering Drugs Market: Market Shares (%) by Region, 2025
  • Figure 4.6 World Cholesterol-Lowering Drugs Market: Revenues ($m) by National Market, 2014
  • Figure 4.7 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2014
  • Figure 4.8 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2019
  • Figure 4.9 World Cholesterol-Lowering Drugs Market: Market Shares (%) by National Market, 2025
  • Figure 4.10 US Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.11 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.12 EU5 Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), 2014-2025
  • Figure 4.13 German Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.14 French Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.15 UK Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.16 Italian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.17 Spanish Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.18 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.19 BRIC Cholesterol-Lowering Drugs Market Forecast: Revenues ($m), 2014-2025
  • Figure 4.20 Chinese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.21 Brazilian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.22 Russia Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.23 Indian Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 4.24 Japanese Cholesterol-Lowering Drugs Market Forecast: Revenues ($m) and AGR (%), 2014-2025
  • Figure 5.1 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2014
  • Figure 5.2 Statins and Fixed-Dose Combinations Market Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.3 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2019
  • Figure 5.4 Statins and Fixed-Dose Combinations Market: Market Shares (%), 2025
  • Figure 5.5 AstraZeneca/Shionogi: Crestor Revenue ($m) and AGR (%), 2009-2014
  • Figure 5.6 AstraZeneca/Shionogi: Crestor Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.7 Pfizer: Lipitor Revenue ($m) and AGR (%), 2009-2014
  • Figure 5.8 Pfizer: Lipitor Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.9 Kowa: Livalo Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.10 Novartis: Lescol/Lescol XL Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.11 Merck: Zocor Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.12 Merck: Vytorin Revenue ($m) and AGR (%), 2014-2025
  • Figure 5.13 Pfizer: Caduet Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.1 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs: Market Shares (%), 2014
  • Figure 6.2 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%), 2019
  • Figure 6.4 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market: Market Shares (%), 2025
  • Figure 6.5 Merck: Zetia Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.6 Daiichi Sankyo: Welchol Revenue ($m) and AGR (%), 2014-2025
  • Figure 6.7 AbbVie: Tricor Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.1 PCSK9 Inhibitors Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.2 PCSK9 Inhibitors Market: Market Shares (%), 2015
  • Figure 7.3 PCSK9 Inhibitors Market: Market Shares (%), 2019
  • Figure 7.4 PCSK9 Inhibitors Market: Market Shares (%), 2025
  • Figure 7.5 Sanofi/Regeneron: Praluent Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.6 Amgen: Repatha Revenue ($m) and AGR (%), 2014-2025
  • Figure 7.7 Pfizer: RN316 (Bococizumab) Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.1 Novel Cholesterol-Lowering Drugs: Market Shares (%), 2014
  • Figure 8.2 Novel Cholesterol-Lowering Drugs Forecast: Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.3 Novel Cholesterol-Lowering Drugs Market: Market Shares (%), 2019
  • Figure 8.4 Novel Cholesterol-Lowering Drugs Market: Market Shares (%), 2025
  • Figure 8.5 Merck: MK-0859 (Anacetrapib) Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.6 Aegerion Pharmaceuticals: Juxtapid (Lomitapide) Revenue ($m) and AGR (%), 2014-2025
  • Figure 8.7 Isis Pharmaceuticals/Sanofi: Kynamro (Mipomersen) Revenue ($m) and AGR (%), 2014-2025
  • Figure 9.1 Leading Cholesterol-Lowering Drug Manufacturers: Revenue ($m), 2014
  • Figure 9.2 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2014
  • Figure 9.3 Leading Cholesterol-Lowering Drug Manufacturers: Revenues ($m), 2019
  • Figure 9.4 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2019
  • Figure 9.5 Leading Cholesterol-Lowering Drug Manufacturers: Revenues ($m), 2025
  • Figure 9.6 Leading Cholesterol-Lowering Drug Manufacturers: Market Shares (%), 2025
  • Figure 9.7 AstraZeneca: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.8 Merck: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.9 Pfizer: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.10 Kowa: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.11 Daiichi Sankyo: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.12 AbbVie: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.13 Novartis: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.14 Sanofi: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 9.15 Amgen: Cholesterol-Lowering Drugs: Revenue ($m) and AGR (%) 2014-2025
  • Figure 10.1 Porter's Five Forces Analysis of the Cholesterol-Lowering Drugs Market, 2015-2025
  • Figure 11.1 World Cholesterol-Lowering Drugs Market Forecast: Revenue ($m), by Segment, 2014-2025

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Accord Healthcare
  • Aegerion Pharmaceuticals
  • Alcon
  • Algorithm SAL
  • Allergan
  • Alynlam Pharmaceuticals
  • Amgen
  • Apotex
  • Astellas Pharma
  • AstraZeneca
  • Aurobindo
  • BASF
  • Bayer
  • Biomarin Pharmaceuticals
  • Blu Caribe
  • Bristol-Myers Squibb
  • Ciba-Geigy
  • Daiichi Sankyo
  • DalCor Pharmaceuticals
  • Dezima Pharma
  • Dr Reddy's Laboratories
  • EGIS Pharmaceuticals
  • Eli Lilly
  • Esperion Therapeutics
  • Eisai
  • Fresenius Medical Care
  • Genzyme Corporation
  • Glenmark
  • Hetero Laboratories
  • Impax Laboratories
  • Intas Pharmaceuticals
  • Isis Pharmaceuticals
  • JW Pharmaceutical
  • Kaneka
  • Kowa
  • Kremers Urban Pharmaceuticals
  • Lek
  • Lupin
  • Merck and Co.
  • Micro Laboratories
  • Miltenyi-Biotec
  • Mylan
  • Novartis
  • Par Pharmaceuticals
  • Pfizer
  • ProEthic Pharmaceuticals
  • ProNova BioPharma
  • Ranbaxy
  • Reckitt Benckiser
  • Recordati
  • Regeneron
  • Roche
  • Sandoz
  • Sanofi
  • Serometrix
  • Shionogi
  • Solvay
  • Sun Pharma
  • Teva
  • Torrent Pharmaceuticals
  • UCB
  • Valeant
  • Warner-Lambert
  • Wockhardt
  • Zydus Cadila

Organisations Mentioned in the Report

  • American College of Cardiology
  • American Heart Association
  • Department of Pharmaceuticals (India)
  • European Society of Cardiology
  • National Health Service
  • National Heart, Lung, and Blood Institute
  • United Nations Department of Economic and Social Affairs
  • US Dietary Guidelines Advisory Committee
  • US Food and Drug Administration
  • World Health Organization
Back to Top